

AMENDMENT TO THE CLAIMS

1. (Original) A method for detecting tissue hypoxia in a mammalian subject by detecting the level of oxygen related protein 150 (ORP150) in a bodily fluid sample whereby an elevated level of ORP150 relative to normal is indicative of an increased risk of heart disease.
2. (Original) The method of claim 1, wherein heart disease is the result of heart failure, chronic heart failure, coronary artery disease, ischaemic cardiomyopathy, myocardial infarction, atherosclerosis, ischaemic stroke, aortic aneurysm, and peripheral vascular disease.
3. (Original) The method of claim 1, wherein the bodily fluid is plasma.
4. (Original) The method of claim 1, wherein the level of ORP150 is determined using an immunoassay.
5. (Original) The method of claim 1, wherein the immunoassay is a lateral flow immunoassay.
6. (Original) The method of claim 1, wherein the immunoassay is a flow-through immunoassay.
7. (Original) The method of claim 1, wherein the antibody is a monoclonal antibody.
8. (Original) The methods of claim 1, which comprises detecting a second marker whereby an elevated level of a second marker is indicative of an increased risk of heart disease.
9. (Original) The method of claim 8, wherein the second marker is a natriuretic peptide.
10. (Original) The method of claim 8, wherein the natriuretic peptide is brain natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (N-BNP).
11. (Original) The method of claim 8, wherein the level of second marker is determined by use of an immunoassay.
12. (Original) The method of claim 8, wherein the immunoassay is a lateral flow immunoassay.
13. (Original) The method of claim 8, wherein the immunoassay is a flow-through immunoassay.
14. (Original) The method of claim 8, wherein the bodily fluid is plasma.

15. (Original) The method of claim 8, wherein the mammalian subject is human.
16. (Original) The method of claim 8, wherein the level of ORP150 is monitored periodically.
17. (Original) The method of claim 8, wherein the level of a second marker is monitored periodically.
18. (Withdrawn) A kit for detecting an increased risk of tissue hypoxia and heart disease in a subject, comprising an antibody for detecting a level of ORP150 in a bodily fluid from a subject.
19. (Withdrawn) The kit of claim 18, further comprising an antibody for measuring the level of a second marker.
20. (Withdrawn) The kit of claim 18, wherein the second marker is N-BNP.
21. (Withdrawn) The kit of claim 18, wherein the second marker is BNP.